The Medical Advisor

This article discusses dosage considerations and key factors related to the use of ivermectin in cancer treatment. Much of the publicly available information regarding ivermectin dosage is based on the standard dosing recommendations developed by Merck for the treatment of parasitic infections. These dosages are often cited without distinction from the higher or alternative dosing regimens that have been explored in cancer-related research. Dosages used for parasitic infections may not correspond to those investigated in oncology studies. Potential dosing strategies may vary depending on several factors, including the patient's body weight, cancer type, cancer stage and grade, overall health status, and liver function. When estimating an ivermectin dosage for cancer-related purposes, multiple considerations are often taken into account. These may include findings from preclinical and clinical cancer studies, published case reports and case series, anecdotal reports, the aggressiven...

Parkinson’s disease, a progressive neurodegenerative disorder, affects millions worldwide, causing debilitating symptoms like tremors, rigidity, and cognitive decline. As researchers continue to explore innovative treatments, one unexpected candidate has emerged: ivermectin, a drug traditionally used to treat parasitic infections. Recent studies have sparked curiosity about its potential neuroprotective effects, prompting questions about whether this widely available medication could offer hope for managing or even slowing the progression of Parkinson’s disease. In this article, we delve into the science behind ivermectin’s potential role in Parkinson’s treatment, examining the latest research, mechanisms of action, and what this could mean for patients seeking new therapeutic options. Can Ivermectin play a key role in treating Parkinson's Disease? Two peer-reviewed papers—one by Warnecke et al. (2020) and another by Wadsworth et al. (2024)—along with a 2021 PhD thesis by ...